THER-07. A PHASE 0 PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF EVEROLIMUS IN VESTIBULAR SCHWANNOMA (VS) AND MENINGIOMA PATIENTS

BACKGROUND: Inhibition of mTORC1 signaling has been shown to diminish growth of NF2 deficient tumors in preclinical studies, and clinical data suggest that everolimus, an orally administered mTORC1 inhibitor, may slow tumor progression in a subset of adult and pediatric NF2 patients with VS. To asse...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Karajannis, Matthias, Wang, Shiyang, Goldberg, Judith, Roland, Thomas, Sen, Chandranath, Placantonakis, Dimitris, Golfinos, John, Allen, Jeffrey, Dunbar, Erin, Plotkin, Scott, Akshintala, Srivandana, Schneider, Robert, Deng, Jingjing, Neubert, Thomas, Giancotti, Filippo, Blakeley, Jaishri
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2019
Ämnen:
Translational Therapeutics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477364/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.214
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk